Compare GUT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GUT | MYGN |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.3M | 625.5M |
| IPO Year | N/A | 1995 |
| Metric | GUT | MYGN |
|---|---|---|
| Price | $6.09 | $6.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $11.82 |
| AVG Volume (30 Days) | 176.3K | ★ 900.6K |
| Earning Date | 01-01-0001 | 02-23-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $825,300,000.00 |
| Revenue This Year | N/A | $0.08 |
| Revenue Next Year | N/A | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.21 |
| 52 Week Low | $4.60 | $3.76 |
| 52 Week High | $7.38 | $15.47 |
| Indicator | GUT | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 45.17 |
| Support Level | $6.01 | $6.09 |
| Resistance Level | $6.10 | $6.31 |
| Average True Range (ATR) | 0.06 | 0.26 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 81.25 | 37.67 |
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.